



## **The Power of Data Sharing**

Eric Jamois 11/14/2023

# pKa Model Development

### **Problem Statement:**

Public datasets for pKa data are limited to ca. 10,000 compounds w/ ca 14,000 pKa values

- Pharma companies have extensive amounts of data
  - → Large potential for expansion of chemical space
  - → Hurdles vs sensitivity of the data

### But:

- Work through contract/legal associated w/ sharing of data
- Large amount of data curation typically required regardless of source
- Complex model construction process (high LOE): Quantum Leap



# pKa Model Development with Bayer Pharma & Crop, Roche & Genentech

pubs.acs.org/jcim

Started in 2012

Best of Both Worlds: Combining Pharma Data and State of the Art Modeling Technology To Improve in Silico pK<sub>3</sub> Prediction

Robert Fraczkiewicz,\*\* Mario Lobell,\*\* Andreas H. Göller,\* Ursula Krenz,\* Rolf Schoenneis,\* Robert D. Clark, and Alexander Hillisch

Simulations Plus, Inc. 42505 10th Street West, Lancaster, California 93534, United States

Continued in 2022/2023

## Simulations Plus Enters New Collaboration to Enhance Machine Learning Models for **Ionization Constants (pKa)**

August 04, 2022

#### Simulations Plus and Global Agrochemicals Leader to Collaborate on **Machine Learning Models**

Data sharing partnership will expand chemical coverage space and improve model performance in support of new approach methodologies to ensure product safety

February 16, 2023 08:30 AM Eastern Standard Time



<sup>&</sup>lt;sup>‡</sup>Global Drug Discovery, Bayer Pharma AG, Wuppertal, Germany

# New pKa Model Development

## **Solution Statement:**

Joint development leading to:

- → 14,176 ionization macroconstants from public sources
- → 19,464 ionization macroconstants from Bayer alone



### Additional data contributions from 2022/2023

- → Roche: 19,000 compounds
- → Genentech: 2,400 compounds
- → Bayer Crop Sci: 4,100 compounds

**→** Total of 70,810 ionization constants

### **RMSE Improvements:**

 $0.792 \rightarrow 0.415$ 

 $0.784 \rightarrow 0.519$ 

 $1.146 \rightarrow 0.556$ 



# **Model Development Timeline**

#### Timeline:

Contracts Signed: 7/15/2022 and 10/3/2022

Data Obtained: 7/20/2022 and later

Model development: 7/20/2022 – 4/13/2023

Final Model Selection: 4/14/2023

Commercial Release: Jun. 2023





#### **Business Model**

- Data: Ownership to customer License to SLP
- Model development: SLP
- Model validation & Publication: Joint
- Model(s): Ownership to SLP License to customer
- Cost to customer: \$0 | Royalty to customer: \$0

# **Areas of Active**



# **Exploration**

### **ChemInformatics**

- Tautomer-independent models
- Automated data curation
- Al technologies

### **Chemistry space**

- BRo5 (PROTAC)
- Macrocyles

#### **Models**

- Clearance / microsomal stability
- Solubility
- Plasma Protein Binding
- Transporters
- CYP Induction
- Intestinal permeability
- UGT metabolism

